Online Only Articles

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

Unite d’Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France;EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France
Unite d’Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France
Tulane School of Medicine, Louisiana Center for Bleeding and Clotting Disorders, New Orleans, LA, USA
Unite d’Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France;EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France
EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France
Unite d’Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France;EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France
Vol. 103 No. 4 (2018): April, 2018 https://doi.org/10.3324/haematol.2017.185330